



Please type a plus sign (+) inside this box → +

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1647

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission **8**

Application Number **09/817,360**

Filing Date **March 20, 2001**

First Named Inventor **GERMAN, MICHAEL S.**

Group Art Unit **1647**

Examiner Name **Unassigned**

**OCT 30 2002**

**RECEIVED**

**TECH CENTER 1600/2900**

### ENCLOSURES (check all that apply)


- Fee Transmittal Form
- Fee Attached
- Response to Restriction Requirement
- After Final
- Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement Form/SB/08A
- Response to Missing Parts/Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

- Assignment Papers (for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s) \_\_\_\_\_

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please identify below):
  - 1. Return Receipt Postcard

Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	CAROL L. FRANCIS, REG. NO. 36,513	
Signature		
Date	October 23, 2002	

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: October 23, 2002.

Typed or printed name	Steven F. Goldstein	Date	October 23, 2002
Signature			

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

# 9/K.T.  
10/30

## CERTIFICATE OF MAILING

ELECT. / A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	October 23, 2002

RECEIVED

<b>RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT</b>  Address to: Box Patent Application Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket Confirmation No.	UCSF-129CIP 2345	OCT 30 2002
	First Named Inventor	Micahel S. German	
	Application Number	09/817,360	TECH CENTER 1600/29
	Filing Date	March 20, 2001	
	Group Art Unit	1635	
	Examiner Name	Brian A. Whitman	
	Title	"Production of Pancreatic Islet Cells and Delivery of Insulin"	

Sir:

This communication is responsive to the Office Action mailed September 27, 2002, which set a one-month period for reply, making this response due on or before October 27, 2002.

Prior to examination of the application on the merits, please enter the following amendments:

## AMENDMENTS

IN THE CLAIMS

Please cancel claims 1-11, 17 and 24 without prejudice as being drawn to a non-elected group.

Please add new claims 28-30.

Please replace the pending claims with their correspondingly numbered claims below.

A/  
12. (Amended) A method for producing an islet cells in vitro, the method comprising: introducing a nucleic acid molecule into a precursor cell *in vitro*, the nucleic acid molecule encoding an islet transcription factor, said introducing being in an amount sufficient for production of the islet transcription factor and production of islet cells.

13. The method of claim 12, wherein the islet transcription factor is neurogenin3.

N.E.